Skip to content

A prospective randomized controlled clinical trial to compare the surgical outcomes of laparoscopic hepatectomy and open hepatectomy for NAFLD-HCC

A prospective randomized controlled clinical trial to compare the surgical outcomes of laparoscopic hepatectomy and open hepatectomy for NAFLD-HCC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067264
Enrollment
Unknown
Registered
2023-01-01
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

laparoscopy group:Laparoscopic resection
laparotomy group :Laparotomy resection

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Preoperative diagnosis of NAFLD-HCC: The diagnostic criteria for HCC were in accordance with the clinical diagnostic criteria for HCC established by the American Association for the Study of Liver Diseases (AASLD). NAFLD: 1. Exclude all chronic liver diseases that may cause liver cancer (such as chronic viral hepatitis B, chronic viral hepatitis C, alcoholic liver disease, autoimmune liver disease, hemochromatosis, primary sclerosing cholangitis, etc.). 2. Previous or current abdominal color ultrasound examination indicated the presence of fatty liver, alcohol intake =25 kg/m^2, waist circumference: male >=94cm, female >=88cm; 110 mg/dL fasting blood glucose or a diagnosis of type 2 diabetes; Lipid metabolism disorders: triglycerides > 1.7 mmol/L (150 mg/dL), HDL =130/85 mmHg or undergoing antihypertensive treatment.

Exclusion criteria

Exclusion criteria: 1. Liver resection combined with other organ operations except gallbladder; 2. Preoperative impact examination indicated that the tumor obviously invaded the portal vein or hepatic artery; 3. Any previous tumor therapy, such as PVE, TACE, targeting, immunology or systemic combination therapy; 4. Liver function Child-Pugh grade C; 5. Extrahepatic metastasis or invasion of other organs was found during the operation; 6. Patients who have not signed the informed consent of the subjects in this experiment.

Design outcomes

Primary

MeasureTime frame
operative combidity;

Secondary

MeasureTime frame
5-year overall survial;5-year tumor-free survival rate;intraoperative related events;incidence of incisional hernia;health quality of life assessment;

Countries

China

Contacts

Public ContactJiang Li

West China Hospital of Sichuan University

jl339@126.com+86 189 8060 6338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026